Search / Trial NCT00001782

Areas of Brain Responsible for Understanding American Sign Language

Launched by NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE (NINDS) · Dec 9, 2002

Trial Information

Current as of October 22, 2024

Completed

Keywords

Deafness Hemisphere Dominance Language Plasticity Speech R Tms

Description

The purpose of this protocol is to determine if the right hemisphere activation associated with perception of American Sign Language (ASL) in deaf subjects and in normal hearing individuals raised by deaf parents (who learned ASL before written English) is necessary for appropriate understanding of ASL.

Gender

ALL

Eligibility criteria

  • Subject age between 18 and 65 years.
  • Adult hearing offsprings of deaf parents.
  • Congenitally deaf individuals.
  • Intact hearing volunteers.
  • No subjects with personal or family history of seizures or other neurological or demyelinating disorders.
  • No pregnant women tested after urine pregnancy test.
  • No subjects with severe coronary disease.
  • No subjects with metal in the cranium except mouth.
  • No subjects with intracardiac lines and implanted medication pumps.
  • No subjects with increased intracranial pressure as evaluated by clinical means.
  • No subjects with cardiac pacemakers.
  • No subjects with an intake of neuroleptics.

About National Institute Of Neurological Disorders And Stroke (Ninds)

The National Institute of Neurological Disorders and Stroke (NINDS) is a leading component of the National Institutes of Health (NIH), dedicated to advancing our understanding of the brain and nervous system through innovative research. NINDS sponsors and conducts clinical trials aimed at developing effective treatments and improving patient outcomes for a wide range of neurological disorders, including stroke, epilepsy, multiple sclerosis, and neurodegenerative diseases. By fostering collaboration among researchers, healthcare providers, and patient communities, NINDS plays a pivotal role in transforming scientific discoveries into clinical applications, ultimately enhancing the quality of life for individuals affected by neurological conditions.

Locations

Bethesda, Maryland, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0